- Home
- PYN vs INTS Comparison
PYN vs INTS Comparison
Compare PYN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- INTS
- Stock Information
- Founded
- PYN 2002
- INTS 2012
- Country
- PYN United States
- INTS United States
- Employees
- PYN N/A
- INTS N/A
- Industry
- PYN Investment Managers
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- INTS Health Care
- Exchange
- PYN Nasdaq
- INTS Nasdaq
- Market Cap
- PYN 33.5M
- INTS 33.4M
- IPO Year
- PYN N/A
- INTS 2023
- Fundamental
- Price
- PYN $5.91
- INTS $2.23
- Analyst Decision
- PYN
- INTS Strong Buy
- Analyst Count
- PYN 0
- INTS 3
- Target Price
- PYN N/A
- INTS $8.50
- AVG Volume (30 Days)
- PYN 19.9K
- INTS 26.6K
- Earning Date
- PYN 01-01-0001
- INTS 03-13-2025
- Dividend Yield
- PYN 5.07%
- INTS N/A
- EPS Growth
- PYN N/A
- INTS N/A
- EPS
- PYN N/A
- INTS N/A
- Revenue
- PYN N/A
- INTS N/A
- Revenue This Year
- PYN N/A
- INTS N/A
- Revenue Next Year
- PYN N/A
- INTS N/A
- P/E Ratio
- PYN N/A
- INTS N/A
- Revenue Growth
- PYN N/A
- INTS N/A
- 52 Week Low
- PYN $4.84
- INTS $1.50
- 52 Week High
- PYN $6.60
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- PYN 65.73
- INTS 49.26
- Support Level
- PYN $5.79
- INTS $1.84
- Resistance Level
- PYN $5.89
- INTS $2.27
- Average True Range (ATR)
- PYN 0.05
- INTS 0.28
- MACD
- PYN 0.01
- INTS -0.01
- Stochastic Oscillator
- PYN 100.00
- INTS 56.36
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.